Halozyme to Report Third Quarter 2024 Financial and Operating Results
Halozyme Therapeutics (NASDAQ: HALO) has announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024, after market close. The company will host a conference call the same day at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. Investors can access the call through pre-registration and view a live webcast through the company's investor relations website.
Halozyme Therapeutics (NASDAQ: HALO) ha annunciato che rilascerà i suoi risultati finanziari e operativi del terzo trimestre 2024 giovedì 31 ottobre 2024, dopo la chiusura del mercato. L'azienda terrà una conferenza telefonica lo stesso giorno alle 13:30 PT/16:30 ET per discutere i risultati. Gli investitori possono accedere alla chiamata tramite pre-registrazione e visualizzare una diretta web attraverso il sito web delle relazioni con gli investitori dell'azienda.
Halozyme Therapeutics (NASDAQ: HALO) ha anunciado que publicará sus resultados financieros y operativos del tercer trimestre de 2024 el jueves 31 de octubre de 2024, después del cierre del mercado. La compañía llevará a cabo una conferencia telefónica el mismo día a la 1:30 p.m. PT/4:30 p.m. ET para discutir los resultados. Los inversores pueden acceder a la llamada mediante preinscripción y ver una transmisión en vivo a través del sitio web de relaciones con inversores de la compañía.
Halozyme Therapeutics (NASDAQ: HALO)는 2024년 3분기 재무 및 운영 결과를 2024년 10월 31일 목요일, 시장 마감 후 발표할 예정이라고 발표했습니다. 회사는 같은 날 오후 1시 30분 PT/오후 4시 30분 ET에 결과를 논의하기 위해 컨퍼런스 콜을 개최합니다. 투자자는 사전 등록을 통해 전화를 이용할 수 있으며, 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트를 시청할 수 있습니다.
Halozyme Therapeutics (NASDAQ: HALO) a annoncé qu'elle publiera ses résultats financiers et opérationnels du troisième trimestre 2024 le jeudi 31 octobre 2024, après la clôture du marché. La société organisera une conférence téléphonique le même jour à 13h30 PT/16h30 ET pour discuter des résultats. Les investisseurs peuvent accéder à l'appel par préinscription et visionner une diffusion en direct via le site Web des relations avec les investisseurs de la société.
Halozyme Therapeutics (NASDAQ: HALO) hat angekündigt, dass am Donnerstag, den 31. Oktober 2024, nach Marktschluss die Finanz- und Betriebsergebnisse für das dritte Quartal 2024 veröffentlicht werden. Das Unternehmen wird am selben Tag um 13:30 Uhr PT/16:30 Uhr ET eine Konferenzschaltung abhalten, um die Ergebnisse zu besprechen. Investoren können über eine Voranmeldung an dem Anruf teilnehmen und eine Live-Übertragung über die Investor-Relations-Website des Unternehmens ansehen.
- None.
- None.
Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813747.
A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-third-quarter-2024-financial-and-operating-results-302285129.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When will Halozyme (HALO) release Q3 2024 earnings?
What time is Halozyme's (HALO) Q3 2024 earnings call?
How can I access Halozyme's (HALO) Q3 2024 earnings call?
